FDA Changes CAR-T REMS Education, Adverse Event Reporting Requirements

Changes to the Risk Evaluation and Mitigation Strategy (REMS) for all six approved CAR-T cell therapies remove the requirement for providers to engage in specific educational activities and allow them to report adverse events directly to the FDA’s MedWatch reporting system.
Source: Drug Industry Daily